A
Axcynsis Therapeutics
A platform-based biotechnology company
About Axcynsis Therapeutics
Axcynsis Therapeutics is a clinical-stage biotechnology company focused on developing Antibody-X Conjugate (AXC) therapies for cancer treatment. Founded in February 2022 by Dr. Zou Bin, the company was initially named Tetris Therapeutics before rebranding to Axcynsis Therapeutics in July 2022 to better reflect its core technology in AXC Synthesis. Headquartered in Singapore, with operations in China and the United States, the company aims to address unmet medical needs in oncology by creating targeted cancer therapies.
The company's founder and CEO, Dr. Zou Bin, is a seasoned executive with a background in drug discovery and investment. Before founding Axcynsis, he was the CEO of Shanghai Blueray Biopharma and a Principal Scientist at the Novartis Institute for Tropical Disease. His experience is complemented by a management team and advisory board with extensive expertise in biology, chemistry, and clinical operations. Axcynsis secured $15 million in a seed funding round in May 2022, led by Trinity Innovation Bioventure Singapore (TIBS), where Dr. Zou previously served as Managing Director.
Axcynsis' business revolves around its proprietary technology platform designed to create next-generation Antibody-Drug Conjugates (ADCs). The platform integrates three core technologies: AxcynMAB™, AxcynCYS™, and AxcynDOT™. AxcynMAB™ is an antibody discovery platform that uses computational technologies to develop high-performance antibodies. AxcynCYS™ enables site-specific conjugation to produce a highly homogeneous ADC product, which allows for precise control over the drug-to-antibody ratio (DAR). AxcynDOT™ is a proprietary payload, derived from the FDA-approved drug Trabectedin, designed with a distinct mechanism of action to overcome drug resistance and improve the safety profile compared to the parent drug. This integrated approach allows the company to develop a pipeline of AXC candidates that selectively deliver cytotoxic payloads to cancer cells, minimizing damage to healthy tissue.
The company's lead product candidate, AT03-65, is a CLDN6-targeting ADC for treating advanced solid tumors. In early 2025, Axcynsis received Investigational New Drug (IND) clearance from the U.S. FDA to initiate a Phase 1 clinical trial for AT03-65. The company's business model focuses on advancing its pipeline of ADC candidates through clinical development, with the goal of addressing significant unmet medical needs in oncology. The company serves the biopharmaceutical market, developing therapies for cancer patients who have exhausted standard treatment options.
Source: Dealroom company dataNews
Open roles
Axcynsis Therapeutics in the Singapore ecosystem
The Axcynsis Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Axcynsis Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Axcynsis Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

